Testosterone undecanoate is a long-acting ester of testosterone used to treat male hypogonadism, available in both injectable and oral forms. What sets it apart from the more familiar testosterone enanthate and cypionate is its pharmacokinetic profile: the injectable version requires roughly four injections per year instead of the biweekly (or more frequent) shots needed with shorter-acting esters, while the oral version bypasses a metabolic bottleneck that historically made swallowing testosterone useless. The drug’s unusual absorption pathway, its practical advantages, and some distinctive safety concerns make it worth understanding on its own terms.
How It Gets Into the Bloodstream
Most oral medications are absorbed from the gut into the portal vein, which feeds directly into the liver. The liver is efficient at breaking down testosterone before it ever reaches the rest of the body. This “first-pass” destruction is why simply swallowing plain testosterone does not raise blood levels in any meaningful way. Testosterone undecanoate sidesteps this problem because of its chemical structure: the undecanoate ester makes the molecule highly fat-soluble, so it gets absorbed through the intestinal lymphatic system instead of the portal vein, bypassing the liver on its initial pass into the circulation.1PubMed Central. An oral lipidic native testosterone formulation that is absorbed independent of food Early research in animals confirmed that although the absolute amount of testosterone undecanoate reaching the lymph was small, it was the main factor determining how much testosterone ultimately became available in the body after an oral dose.2International Journal of Pharmaceutics. The effect of drug lipophilicity and lipid vehicles on the lymphatic absorption of various testosterone esters
Because the lymphatic route depends on fat digestion, the amount of fat in a meal eaten alongside an oral dose has a direct impact on absorption. One study found that when hypogonadal men took the older oral formulation (marketed in many countries as Andriol Testocaps) with a meal containing roughly 19 grams of fat, testosterone exposure was several times higher than when the same dose was taken with a very low-fat meal.3PubMed Central. The effect of food composition on serum testosterone levels after oral administration of Andriol Testocaps Increasing fat beyond about 19 grams did not boost absorption much further, suggesting a ceiling effect. Newer self-emulsifying oral formulations (such as the product approved in the United States as Jatenzo and a similar product called Kyzatrex/Tlando) were specifically designed to reduce this food dependence. In clinical testing, these newer capsules still produced higher testosterone levels when taken with a meal, but even in a fasted state, predicted average levels remained within the normal reference range for most men.4PubMed Central. Dietary fat modulates the testosterone pharmacokinetics of a new self-emulsifying formulation of oral testosterone undecanoate in hypogonadal men
The Injectable Version and Its Dosing Schedule
Injectable testosterone undecanoate is dissolved in oil (usually castor oil) and delivered as a deep intramuscular injection, typically into the gluteal muscle. The oil depot releases testosterone slowly, producing a much longer-lasting effect than the enanthate or cypionate esters most men in the United States and Europe are familiar with. Early pharmacokinetic studies found that a single injection could keep serum testosterone within the normal adult male range for at least seven weeks, with a terminal half-life in the range of roughly 19 to 34 days depending on the oil vehicle used.5PubMed. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men6PubMed. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies
In long-term clinical use, the standard protocol is a 1,000 mg injection given every 10 to 14 weeks after an initial loading phase. A pivotal long-term study showed that this schedule maintained trough testosterone levels around 14 to 16 nmol/L, comfortably within the normal range, whereas men on biweekly testosterone enanthate consistently fell below 10 nmol/L before their next shot.7The Journal of Clinical Endocrinology & Metabolism. Intramuscular Testosterone Undecanoate: Pharmacokinetic Aspects of a Novel Testosterone Formulation during Long-Term Treatment of Men with Hypogonadism The practical upshot: about four injections per year instead of 17 or more. That difference matters for quality of life. A large electronic health record study found that men on injectable testosterone undecanoate had roughly twice the treatment adherence and were five times more likely to remain on their original therapy at one year compared with men on testosterone cypionate.8Androgens: Clinical Research and Therapeutics. Comparison of Patterns of Use and Clinical Outcomes Between Injections of Testosterone Undecanoate and Testosterone Cypionate: An Electronic Health Record Cohort Study
The smoother pharmacokinetic profile is another advantage. With shorter-acting esters, men often experience supraphysiological peaks shortly after injection followed by troughs that dip below normal before the next dose, sometimes described as a hormonal roller coaster. Testosterone undecanoate produces a much flatter curve, with smaller swings between peak and trough.9PubMed Central. Pharmacokinetics of testosterone therapies in relation to diurnal variation of serum testosterone levels as men age
Oral Testosterone Undecanoate in Practice
Until 2019, there was no FDA-approved oral testosterone product in the United States. The approval of Jatenzo (testosterone undecanoate capsules) changed that, followed by Tlando and Kyzatrex. In a pivotal trial, about 87% of men with hypogonadism who took the oral formulation achieved average testosterone concentrations within the normal range, with a mean value around 489 ng/dL.10The Journal of Clinical Endocrinology & Metabolism. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men The typical dosing is twice daily with food, which is obviously more frequent than quarterly injections but avoids needles entirely.
Men who have switched from other testosterone therapies to oral testosterone undecanoate report significant improvements in satisfaction. In one trial measuring patient-reported outcomes, convenience scores jumped from about 62 out of 100 at baseline to nearly 87 at six months, and global satisfaction followed a similar trajectory.11PubMed Central. Patient Satisfaction with Oral Testosterone Undecanoate in Men Who Received Prior Testosterone Therapy: An Open-Label, Single-Center Clinical Trial That convenience gain is real, but the twice-daily dosing does require consistency. Missing doses or taking them without food can lead to dips in testosterone levels, which is a trade-off compared to the set-and-forget nature of an injection every few months.
Effects on Body Composition and Bone
Like other testosterone formulations, testosterone undecanoate produces measurable changes in body composition. A year-long dose-ranging study in 322 older men with symptomatic testosterone deficiency found significant increases in lean body mass and decreases in body fat across all dose groups, with a clear dose-response relationship. Bone mineral density at the lumbar spine and hip also increased at the highest dose tested.12PubMed. Effects of oral testosterone undecanoate therapy on bone mineral density and body composition in 322 aging men with symptomatic testosterone deficiency: a 1-year, randomized, placebo-controlled, dose-ranging study Studies in transgender men receiving intramuscular testosterone undecanoate as gender-affirming therapy showed a similar pattern: significant gains in lean mass, though fat mass and bone density did not change over the study periods examined.13PubMed. Effects of intramuscular testosterone undecanoate on body composition and bone mineral density in female-to-male transsexuals
One randomized controlled trial specifically looked at testosterone undecanoate in men with type 2 diabetes. Fat mass decreased by about 2.4 kg and lean mass increased by about 2.1 kg compared with placebo, but these body composition improvements did not translate into better insulin resistance or blood sugar control.14Diabetes Care. Effect of Testosterone Treatment on Glucose Metabolism in Men With Type 2 Diabetes: A Randomized Controlled Trial A separate study suggested that the metabolic response depends on how severely testosterone is deficient to begin with: men with more severe deficiency saw improvements in sexual function but not metabolic markers during the initial treatment phase, while men with milder deficiency saw improvements in weight and waist circumference instead.15PubMed. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study) The relationship between testosterone replacement and metabolic health is clearly not as straightforward as “more testosterone, less diabetes.”
Pulmonary Oil Microembolism
The injectable form carries a unique safety concern not shared by other testosterone esters: pulmonary oil microembolism, usually abbreviated POME. This happens when a small amount of the oil vehicle enters the bloodstream during or shortly after injection and travels to the lungs. The symptoms can be alarming: sudden cough, shortness of breath, chest tightness, sometimes flushing or dizziness. In the United States, the injectable product (marketed as Aveed) carries a boxed warning about POME and must be administered in a healthcare setting with a required observation period afterward. This is managed through a formal risk-management program.
The actual incidence, though, is very low. A postmarketing safety analysis of roughly 90,000 Aveed injections found a spontaneously reported POME rate below 0.1% per injection. Most episodes resolved within 30 minutes, and over 60% required no medical intervention at all.16Oxford Academic (Sexual Medicine). Occurrence of Pulmonary Oil Microembolism After Testosterone Undecanoate Injection: A Postmarketing Safety Analysis A broader literature review spanning nearly 8,000 patients across 29 studies found 88 reported incidents of POME or cough, with almost all cases resolving spontaneously within an hour.17International Journal of Impotence Research. Occurrence of pulmonary oil microembolism (POME) with intramuscular testosterone undecanoate injection: literature review The mandatory in-office administration and observation period in the U.S. is a genuine inconvenience, but the event itself is rare and almost always self-limiting. In many other countries where the injectable has been available for longer (marketed as Nebido), the risk-management requirements are less restrictive.
Erythrocytosis and Blood Pressure
All forms of testosterone replacement increase red blood cell production. This effect, called erythrocytosis when the hematocrit rises above a certain threshold, is actually the most commonly encountered lab change on testosterone therapy overall, with one meta-analysis finding a roughly threefold greater risk compared with men not on treatment.18Sexual Medicine Reviews. Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male Injectable formulations tend to drive hematocrit higher than gels or oral products, largely because of the supraphysiological peaks that come with less frequent dosing. A long-term observational study of men on injectable testosterone undecanoate found that about 40% experienced polycythemia at some point during follow-up, regardless of age.19PubMed. Long-term testosterone undecanoate treatment in the elderly testosterone deficient male: An observational cohort study
Rising hematocrit ties into blood pressure. Studies of oral testosterone undecanoate have documented small but statistically significant increases in ambulatory blood pressure. One trial found a mean rise in 24-hour systolic blood pressure of about 3.8 mmHg after four months of treatment, with larger rises in men whose hematocrit increased the most. In the top quartile of hematocrit increase (a rise of 6% to 14%), the average blood pressure bump was about 8.3 mmHg, which is clinically meaningful.20PubMed. Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men A separate trial of the oral formulation found somewhat smaller increases of about 1.7 to 1.8 mmHg at the five- and six-month marks.21PubMed Central. Effects of the oral testosterone undecanoate Kyzatrex on ambulatory blood pressure in hypogonadal men The practical lesson is that hematocrit monitoring is not just a lab formality: it can serve as an early signal that blood pressure may be climbing, and dose adjustments or therapeutic phlebotomy can be considered before it becomes a problem.
Prostate Safety Over Time
Concerns about testosterone therapy and the prostate are long-standing, and testosterone undecanoate has some of the longest follow-up data available on this question. A four-year study of injectable testosterone undecanoate found that prostate volume increased modestly during the first year (from about 20 mL to 22 mL on average) and then stabilized for the remaining three years. PSA levels followed a similar pattern: a small initial rise that plateaued.22PubMed. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate An earlier study of oral testosterone undecanoate given to middle-aged men with normal testosterone levels found a 12% increase in prostate volume over the treatment period, with no change in PSA.23PubMed. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men These findings are consistent with the broader literature on testosterone replacement and prostate health: there is typically a small initial adjustment followed by stability, rather than continuous growth. Standard monitoring, including periodic PSA checks and digital rectal exams, remains recommended.
Use in Gender-Affirming Hormone Therapy
Testosterone undecanoate has become an increasingly popular option for transgender men and transmasculine individuals pursuing masculinizing hormone therapy. Its chief practical advantage is the extended dosing interval. A randomized head-to-head trial comparing testosterone undecanoate with testosterone enanthate in transgender men found that both produced equivalent masculinizing effects at one year, with similar changes in hemoglobin, hematocrit, lipids, and hormone levels. The testosterone undecanoate group, however, required only about six injections over the year compared with 18 for the enanthate group, and patients preferred testosterone undecanoate at the study’s end.24PubMed. A Randomized Controlled Trial Comparing Testosterone Enanthate and Testosterone Undecanoate as a Gender Affirming Hormonal Therapy in Trans Males
More broadly, a randomized trial looking at early access to testosterone therapy in transgender and gender-diverse adults (not limited to testosterone undecanoate specifically) found that testosterone treatment produced meaningful reductions in gender dysphoria, depression, and suicidality compared with standard care.25JAMA Network Open. Early Access to Testosterone Therapy in Transgender and Gender-Diverse Adults Seeking Masculinization: A Randomized Clinical Trial For this population, the reduced injection burden of testosterone undecanoate can lower a practical barrier that sometimes contributes to inconsistent use, though the need for in-office administration in the U.S. partially offsets this advantage compared with self-injectable enanthate or cypionate.
Research Into Male Hormonal Contraception
One of the more surprising chapters in testosterone undecanoate’s history is its investigation as a male contraceptive. The principle is straightforward: exogenous testosterone suppresses the brain hormones (LH and FSH) that drive sperm production. If you suppress them deeply enough, sperm counts drop to zero or near zero, effectively rendering a man temporarily infertile.
Clinical trials conducted primarily in Chinese men showed that monthly injections of testosterone undecanoate suppressed spermatogenesis to azoospermia or severe oligospermia in about 95% of participants.26Journal of Andrology. Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese men An earlier trial found that essentially all men receiving the 1,000 mg dose became azoospermic, with suppression reversing after treatment stopped.27The Journal of Clinical Endocrinology & Metabolism. A Clinical Trial of Injectable Testosterone Undecanoate as a Potential Male Contraceptive in Normal Chinese Men Combining testosterone undecanoate with a progestin such as norethisterone enhanced suppression further.28The Journal of Clinical Endocrinology & Metabolism. An Effective Hormonal Male Contraceptive Using Testosterone Undecanoate with Oral or Injectable Norethisterone Preparations
These results have been reproducible, but male hormonal contraception has not made it to market. The suppression rate varies across ethnic populations (the 95% azoospermia rate in Chinese men has not been matched in Western trials), the monthly injection schedule is cumbersome, and regulatory appetite for approving a contraceptive that fails to suppress sperm in every user has been cautious. The research remains active, though, and testosterone undecanoate is one of the lead compounds in ongoing contraceptive development programs.
Mood, Cognition, and Where the Evidence Thins Out
Patients starting testosterone therapy often expect improvements in mood, energy, and mental sharpness, and for many men with genuine hypogonadism, those improvements are real. The evidence specifically linking testosterone undecanoate to cognitive or psychological benefits is thinner than you might hope, though. A 12-month placebo-controlled trial in elderly men with low-normal testosterone found no difference in visuospatial cognition, mood, or quality-of-life scores despite increases in bioavailable testosterone and muscle mass.29PubMed. Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status A study comparing testosterone undecanoate with testosterone enanthate in hypogonadal men found that mood effects were difficult to establish, partly because of wide variability between individuals and differences at baseline.30PubMed. Comparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal men
This is not unique to testosterone undecanoate; the broader literature on testosterone therapy and cognition in older men has been disappointing. The takeaway is not that testosterone replacement has no subjective benefits, but that the strongest documented effects are on sexual function, body composition, and bone density rather than on mental performance or emotional well-being measured by formal scales. Men with markedly low testosterone who report brain fog or low mood often do feel better on treatment, but controlled trials have struggled to capture that consistently with standardized instruments.
Choosing Between Oral and Injectable
For someone starting testosterone undecanoate, the oral-versus-injectable decision usually comes down to a handful of practical factors rather than a clear clinical superiority of one over the other. The injectable version delivers more stable levels with fewer administrations and avoids any food-timing considerations, but requires an in-office visit (in the U.S.) and involves a large-volume intramuscular injection that can be uncomfortable. The oral version allows home administration and eliminates needles but demands twice-daily dosing, ideally with a meal containing some fat, and produces more variable testosterone levels throughout the day.
Cost and insurance coverage play a role as well. The injectable product has been available generically in many countries for years but remains branded (Aveed) and relatively expensive in the United States, partly because the risk-management program adds administrative overhead. The newer oral formulations are similarly priced at the branded level. In countries outside the U.S. where the injectable is sold as Nebido and can be administered without the REMS observation period, cost comparisons shift. There is no single right answer; the best choice depends on whether you value fewer administrations, needle avoidance, cost, or day-to-day flexibility.